File a New Drug Application for vutrisiran
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“File an NDA for vutrisiran.”
What we found
Evidence strength A What the grades mean
Alnylam submitted the NDA for vutrisiran in April 2021, which occurred after the early 2021 deadline.
-
A Alnylam Pharmaceuticals, Inc. 10-Q filed 2021-04-29
“in April 2021, based on the positive HELIOS-A data, we submitted an NDA for vutrisiran.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- File
- Deliverable
- New Drug Application for vutrisiran
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Alnylam Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALNY-023580 · Corrections policy